Top five ophthalmology stories of September

Allergan’s announcement that it would partner with a Native American tribe to protect the intellectual rights to Restasis was the most-read story on Healio.com/OSN in September. Other top stories included business updates and clinical trial results.

Here are the top five stories of September:

1. Allergan enters patent protection deal with Native American tribe, files suit against Imprimis

Allergan announced two recent moves to protect its intellectual property and prevent generic competition. Read more.

2. Lampalizumab trial for geographic atrophy fails to meet endpoint

A phase 3 study of lampalizumab for geographic atrophy failed to meet its primary endpoint of reducing mean change in lesion area. Read more.

3. Visual acuity improvements maintained long term after three-step procedure for keratoconus

Patients with moderate to severe keratoconus who underwent a three-step procedure maintained visual acuity improvements at 2 years. Read more.

4. Ophthotech announces new Zimura clinical trials

Ophthotech will begin an open-label phase 2a clinical trial of Zimura, a complement factor C5 inhibitor for patients with wet age-related macular degeneration. Read more.

5. Johnson & Johnson Vision completes TearScience acquisition

The company announced in August that it would acquire TearScience, which has FDA clearance for products to evaluate meibomian gland health and treat meibomian gland dysfunction, the leading cause of dry eye disease. Read more.